Please find below the affiliations and presentations of the confirmed invited speakers together with the abstract of their oral communication (opens as a pdf in a new window):
Arwyn Jones, PhD
Project Leader | Endocytosis and Drug Delivery
School of Pharmacy and Pharmaceutical Sciences, Cardiff University – Cardiff (United Kingdom) “Cell Binding and Tailored Intracellular Delivery of Macromolecular Therapeutics”
Arwyn gained his PhD in protein biochemistry and crystallography at Birkbeck College University of London. Then he undertook postdoctoral positions investigating membrane traffic on the endocytic pathway at the University of Liverpool and Harvard University. He was then awarded a European Molecular Biology Organization fellowship to work at the European Molecular Biology Laboratory (EMBL), Heidelberg Germany and then continued at the EMBL when he was awarded an Alexander von Humboldt Foundation Scholarship. In 2001 he was appointed as Lecturer in Molecular Cell Biology at the Cardiff School of Pharmacy and Pharmaceutical Sciences at Cardiff University where he is now a Professor in Membrane Traffic and Drug Delivery.
Research projects in his lab fall under themes of cancer cell biology, endocytosis and drug delivery; concentrating on linking fundamental endocytosis research to gain a better understanding of the cellular delivery and intracellular fate of drug delivery vectors and their cargo. In this pursuit he actively collaborates with a number of national and international groups including his recent strong involvement with COMPACT (http://www.compact-research.org/). This is an academic/industrial drug delivery consortium collaborating on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets.
Arwyn has published widely within the fields of endocytosis and drug delivery especially within the remit of early endosomal traffic and the utilization of cell penetrating peptides as drug delivery vectors.
He currently sits on the Editorial Board of the Journal of Controlled Release, and Membranes and his home page can be found here: goo.gl/wT7Jnr
Arwyn is also very active in public engagement with science and has organised a number of large scientific exhibitions: goo.gl/eEziHx
Jean-Luc Lenormand, PhD
Professor | TheReX, TIMC-IMAG, UMR 5525
Univeristy Joseph Fourier – La Tronche (France) “Anticancer treatment using a novel Cell-Penetrating Peptide”
Pr JL Lenormand is professor at the Joseph Fourier University (school of medicine) and has formal training in molecular and cellular biology from Pierre and Marie Curie University (Paris, France) and he worked with Dr SA Leibovitch at the Gustave Roussy Institute (France).
His postdoctoral training was at University of California San Diego (UCSD, USA) studying the regulation of meiosis in Xenopus laevis. Recent publications have focused on the isolation and characterization of a totally new and important cell cycle regulator named Speedy.
Pr JL Lenormand has been also responsible for the R&D department of a French biotech company (formerly Protein’eXpert, now PX Therapeutics) specialized in recombinant proteins production.
Pr. JL Lenormand has recently received a prestigious grant from the European Commission (Marie Curie Excellence Grant, #014320) to develop projects related to protein therapeutics. From this grant, he is now responsible of the HumProTher Laboratory (TIMC-IMAG, UMR 5525) in Grenoble.
Furthermore, he is actively involved into a European training program for graduated students from Italy (Leonardo da Vinci Program “Unipharma-Graduates”, Pr Luciano Saso Director of the Program). The innovative projects of the HumProTher laboratory are related to the development of a new expression system for membrane proteins and the characterization of original delivery vectors for therapeutic proteins. He is a founder of a new biotech company (Synthelis) that has been formed recently in the field of membrane proteins synthesis using a patented cell-free expression system. — Close —
Charlie Gosse, PhD
Researcher | LPN
Centre National de la Recherche Scientifique – Marcoussis (France) “Microdevices to locally electroporate embryos: from the proof-of-concept to the prototype”
Charlie Gosse studied chemistry at the Ecole Normale Supérieure (Paris) before undertaking there a PhD in physical-chemistry. In between the Laboratoire de Physique Statistique and the Département de Chimie he investigated micromanipulation and force measurement with magnetic tweezers, as well as he tried to conceive a bidimensional network of nucleic acids. Subsequently, he flew to Japan to work as a post-doctoral researcher on phage DNA packaging at Keio University (Yokohama).
Back in France he started microfluidics at the Institut Curie (Paris). Since 2002, he is CNRS researcher at the Laboratoire de Photonique et de Nanostructures (Marcoussis). He first developed devices for biomolecule separation and analysis, performing measurements of transport properties and reaction kinetics, using the latter criteria to selectively detect species in complex mixtures. Next, he has been interested in the spatiotemporal dynamics of reactive systems. Implementing relaxation techniques, he devised microchips to study signaling networks at various scales, from biomolecule association to the formation of more complex biological structures such as the mitotic spindle or anterio-posterior axis in mouse embryo. — Close —
Bruno Le Pioufle, Pr
Professor, BIOMIS group director | Institut d’Alembert/CNRS SATIE/BIOMIS
Ecole Normale Supérieure de Cachan – Cachan (France) “Microfluidic devices for the diagnosis or treatment of cells”
B. Le Pioufle is Professor at ENS de Cachan, and is currently working on the design, conception and use of bio-microsystems. His main scientific concerns are 1) the conception of microfluidic biochips for the monitoring of membrane proteins and ion channels and 2) cell biochips. In particular he is working on the conception and design of biodevices for the cell handling and treatment, using dielectrophoresis, electrorotation, bioimpedance, electropermeabilization using either micro or nanopulses. He spent 4 years at University of Tokyo, in the groups of H. Fujita, then in the group of S. Takeuchi. He was Director of LIMMS (International laboratory between CNRS and University of Tokyo). — Close —
Elias Fattal, PhD
Professor | Institut Galien Paris-Sud
Université Paris Sud – Châtenay-Malabry (France) “Safety of inhalable biodegradable nanoparticles”
Elias Fattal is a full professor in Drug Delivery Science at the University of Paris-Sud in Châtenay-Malabry, France and has been President of APGI from 2003 to 2010. He received his Pharmacy Degree (1983) and Ph.D. (1990) from the University of Paris-Sud and followed an internship in Pharmacy at the University of Lille (1984-1986).
After visiting the Department of Pharmaceutical Chemistry at the University of California, San Francisco for a post-doctoral position (1990-1991), he became associate Professor (1992) and full Professor at the University of Paris-Sud (2000). He is heading the Institut Galien Paris Sud.
Over the past 25 years, he has made outstanding fundamental and applied contributions to the fields of drug delivery using nanotechnologies for targeted or local delivery of drugs, nucleic acids and contrast agents. Part of his research is dedicated to nanotoxicology. Several of his inventions have been licensed to the pharmaceutical industry. Recently, he has been involved in the development of an adjuvant to antibiotics able to reduce resistance by adsorbing residual colonic antibiotics (clinical phase I).
Prof. Fattal has authored more than 220 refereed articles and 26 book chapters. He has issued 10 international patents and has received the Pharmaceutical Sciences World Congress (PSWC) Research Achievement Award. He serves in the editorial board of several journals among which Journal of Controlled Release and Nanomedicine NMB. — Close —
Andrew Owen, PhD FRSB
Professor of Pharmacology | Molecular and Clinical Pharmacology
University of Liverpool – Liverpool (United Kingdom) “Preclinical assessment of the immunological safety of nanomedicine candidates”
Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine.
He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group.
His research focuses on the mechanisms that underpin interpatient variability in pharmacokinetics and pharmacodynamics for drugs used in infectious diseases. In recent years a major emphasis has been to employ knowledge of these mechanisms to accelerate translation of nanomedicine candidates to clinical applications. Research funding has been secured from the US National Institutes for Health, the UK Medical Research Council, the European Commission, the UK Engineering and Physical Sciences Research Council, the British Society for Antimicrobial Chemotherapy and the Clinton Health Access Initiative.
Prof. Owen has published over 130 original research papers, review manuscripts and book chapters, and is co-inventor of patents relating to the application of nanotechnology to drug delivery. He is also a Co-Editor in Chief for the Journal of Interdisciplinary Nanomedicine (www.JOINjournal.com). — Close —
Peter Wick, PhD
Head of Laboratory | Particles-Biology Interaction
Swiss Federal Laboratories for Material Science and Technology – St. Gallen (Switzerland) “Reliability and measurement science for HTS Nanomedicine”
Peter Wick heads since 2014 the research laboratory for Particles-Biology Interactions at the Federal Laboratories on Materials Science and Technologies Empa in St. Gallen. He studied and received his PhD in cell- and molecular biology at the University in Fribourg (Switzerland). Thereafter (2002) he moved to Empa and began his research in nanotoxicology among others with the national project NanoRisk, and is now active in further projects of the 7th Framework program of the EC, for example, NANOHOUSE, MARINA, NanoSolutions & Flagship Graphene and is also founded by the SNF NFP64 research program.
His general research interest is to study the interactions of nanomaterials with human barrier tissues in vitro and ex vivo with the purpose to obtain detailed mechanistic information about their uptake, accumulation, transport and effect on different types of cells or entire tissue. In addition he is interested in improvement of currently used acute toxicological test methods to obtain reliable and robust results.
He is author of around 100 publications, including over 60 peer-reviewed papers, in the field of Nanosafety. He is a member of the advisory board of the Swiss Action Plan on Nanomaterials and Editorial Board Member of Nanotoxicology. — Close —
Hisataka Kobayashi, MD, PhD,
Chief scientist | Molecular Imaging Program
National Cancer Institute/ National Institutes of Health – Bethesda (United States) “Enhanced nano-drug delivery into cancer after photoimmunotherapy”
Dr. Hisataka Kobayashi is the Chief Scientist of Molecular Imaging Program, National Cancer Institute/ NIH in Bethesda, Maryland with over 25 year experience in R&D of Bio-medical imaging and drug delivery especially targeting cancer for diagnosis and therapy.
Dr. Kobayashi holds an MD in Radiology, and a PhD in Immunology/Internal Medicine from Kyoto University, Kyoto, Japan, and has written or contributed to >250 articles and >40 invited reviews and book chapters and gave >200 invited lectures and talks in the basic and clinical bio-imaging fields. — Close —
Eric Vibert, PhD, MD
Medical Doctor | Liver Surgery and Transplantation – INSERM U1193
Hôpital Paul Brousse, APHP – Villejuif (France) “Interests and limits of intraoperative fluorescence imagery in liver surgery”
Eric Vibert is a staff liver surgeon at Centre Hépato-Biliaire, Paul Brousse Hospital. He is specialist of the post-operative liver failure and its treatment.
In this field, he is a Co-chairman of the French Hepatectomy On-line Register, Coordinator of iFLOW Projet (Intraoperative Fluorescent Liver Optimization Workup) and Inventor of LIVER SP (IpadApp) to improve surgeon-patient communication before liver surgery. He is also the principal investigator of a French multicentric controled study that evaluated the liver transplantation in patient with resectable perihilar cholangiocarcinoma (TRANSPHIL Study).
His main research interests are biliary disease, hepatocellular carcinoma, postoperative liver insufficiency, and liver transplantation. In HECAM projet, he managed a public-private study with Fluoptics to optimize intraoperative using of ICG camera in surgical treatment of primitive liver tumor. — Close —
Nicolas Grenier, MD
Professor of Radiology | Service de Radiologie
CHU de Bordeaux – Bordeaux (France) “Prostatic cancer and optical nanoprobes for theragnostic”
Nicolas GRENIER, 58, obtained his MD in 1980 and his professorship in Radiology from the University of Bordeaux in 1990. During his fellowship, he spent 6 months in Canada at the University of Montreal and 6 months in Philadelphia at the University of Pennsylvania.
He has been chef de service of Radiology from 1993 to now, in the Groupe Hospitalier Pellegrin of the CHU de Bordeaux. He has been President of the European Society of Urogenital Radiology (ESUR) from 2000 to 2002, President of the European Society of Molecular and Functional Imaging in Radiology (ESMOFIR) from 2011 to 2014 and President of the French Academic College of Radiology (CERF) from 2012 to 2015.
His clinical fields of interest are urogenital and vascular imaging, using mainly MR imaging and ultrasounds. In the field of research, from 2002 to 2013, in the UMR-CNRS 5231, he developed methods for functional MR imaging of the kidney, for cellular imaging in the kidney using nanoparticles of iron oxide to identify intrarenal inflammatory processes and to track labeled mesenchymal stem cells. At the same time, he participated with Chrit Moonen to the development of focused US in the abdomen and evaluated the role of US-elastography in diffuse renal diseases for the diagnosis of fibrosis.
From 2013, he participated to a consortium with the CEA-LETI from Grenoble to develop a new bifunctional imaging system, US-optical, for diagnosis of prostatic carcinoma. Now, he particpated to the validation of an anti-PSMA Ab-fragment to target prostatic carcinoma using optical imaging and lipid nano-vehicles (Lipidots®). He is actually working, in association with the F Couillaud’s group in the UMR 5536, on new nanotechnologies for innovative theragnostic approaches. — Close —
Twan Lammers, PhD, DSc
Professor | ExMI – Nanomedicine and Theranostics
RWTH Aachen University Clinic – Aachen (Germany) “Image-guided drug delivery”
Twan Lammers obtained a DSc degree in Radiation Oncology from Heidelberg University in 2008 and a PhD degree in Pharmaceutics from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at the Institute for Experimental Molecular Imaging at the University Clinic of RWTH Aachen.
In 2014, he was appointed as professor of Nanomedicine and Theranostics at RWTH Aachen. Since 2012, he has also worked as a part-time assistant professor (10% FTE) at the Department of Targeted Therapeutics at the University of Twente. He published over 100 research articles and reviews, and received several awards. His primary research interests include drug targeting to tumors, image-guided drug delivery and tumor-targeted combination therapies. — Close —
Pierre Yves Benhamou, MD, PhD
Head of Department, University Hospital | LBFA Laboratoire de Bioenergetique Fondamentale et Appliquee
Centre Hospitalier Universitaire de Grenoble – Grenoble (France) “Nanomedicine for a Cellular Therapy of Diabetes”
Pierre Y. Benhamou (MD, PhD), 55, Professor of Endocrinology, Head of the Department of Endocrinology, Diabetes and Nutrition, University Hospital, Grenoble, France. He graduated from Grenoble University in 1988, and performed a 3-year research fellowship at UCLA in 1991.
He is founder and head of the Swiss-French clinical research network (GRAGIL network) devoted to pancreatic islet transplantation since 1998. He is also founder and head of the Telemedicine and Advanced Technology Study Group of the Societe Francophone du Diabete since 2005.
He authored and coauthored more than 110 scientific papers referenced in the MedLine database. He has large experience in multicentric clinical research in the field of diabetes, and was principal investigator of several trials. He conducted 2 nationwide trials that demonstrated the efficiency of pancreatic islet transplantation for the management of brittle type 1 diabetes (Gragil and Trimeco Trials), and is currently conducting a medico-economic study in this field (Stabilot Trial). He is also a co-investigator in an european project aiming at designing a bioartificial pancreas, in collaboration with CEA (Biocapan Project). He promotes the use of telemedical solutions aiming at improving metabolic results and quality of care of diabetic patients.
In the past 5 years, he was investigator in 3 large multicentric trials testing such solutions. He also is investigator in the DIABELOOP project aiming at creating an artificial pancreas connecting a glucose sensor and an insulin pump. — Close —
Pierre Nassoy, PhD
CNRS Senior Scientist | LP2N
Institut d’Optique d’Aquitaine – Talence (France) “The Cellular Capsules Technology”
Pierre Nassoy, 46, obtained his PhD in Soft Condensed Matter Physics from the University of Paris 6 in 1996 after graduating from the Ecole Supérieure de Physique et Chimie Industrielles de la Ville de Paris in 1991. He started to work in biophysics as a post-doc at the University of British Columbia, Vancouver, Canada (advisor: Evan Evans). He then got a CNRS as a junior scientist at the Institut Curie, where he develeoped optico-mechanical assays to investigates the mechanical properties of cellular membranes.
In 2012, he moved to the Institut d’Optique d’Aquitaine and pursued a new research axis based on the design and imaging of in vitro micro-tissues with applications to high throughput screening of drugs in cancer biology and to tissue engineering. — Close —